option
Home
Flash News
Content
AlbertHernández
AlbertHernández
October 9, 2025

SpotitEarly, a biotech startup launching at TechCrunch Disrupt 2025, is developing an AI-powered at-home cancer test using dogs’ scent detection. Trained beagles analyze breath samples for breast, colorectal, prostate, and lung cancers with 94% accuracy, validated by AI monitoring. Priced at $250 per test, it aims to undercut competitors like Grail’s $950 Galleri test. The company raised $20.3M to expand clinical trials and plans a 2025 rollout via physician networks. Founded in 2020, SpotitEarly prioritizes dog welfare, treating them as team members.

SpotitEarly, a biotech startup launching at TechCrunch Disrupt 2025, is developing an AI-powered at-home cancer test using dogs’ scent detection. Trained beagles analyze breath samples for breast, colorectal, prostate, and lung cancers with 94% accuracy, validated by AI monitoring. Priced at $250 per test, it aims to undercut competitors like Grail’s $950 Galleri test. The company raised $20.3M to expand clinical trials and plans a 2025 rollout via physician networks. Founded in 2020, SpotitEarly prioritizes dog welfare, treating them as team members.
Comments (0)
0/300
OR